GLOBAL COLON AND RECTAL CANCER DRUGS MARKET
Colon and rectal cancer show several similar features. According to the U.S. The American Cancer Society (ACS) rate of colorectal cancer is growing among the millennial population. ACS also predicts, in 2018, colon cancer will reach up to 97,220 new patients along with 43,030 patients with rectal cancer in the American territory. Likewise, because of the growing chances of colorectal cancer, in May 2018, ACS developed its rules and regulations for colorectal cancer screenings and suggested beginning colorectal cancer screening at the age of 45 instead of age of 50.
Rising incidence and the majority of colon and rectal cancer globally and advancing investigation and development studies for colorectal cancer therapy had anticipated pushing the development of the colon and rectal cancer market soon. According to the data results of the American Cancer Society (ACS), in February 2018, colorectal cancer is the third standard cancer interpreted in men and women in the American regional market.
Based on the data findings of the Center for Disease Control and Prevention (CDC), in 2014, almost 139,992 American citizens were diagnosed with colorectal cancer, which includes 66,596 female patients and 73,396 male patients. In these data findings, almost 51,651 casualties occurred in the American market due to colorectal cancer. Among these casualties, 24,517 were women, and 27,134 were men patients. Likewise, based on the data report in 2012, gathered by the World Health Organization (WHO), colorectal cancer is the third standard cancer among male patients and the second standard cancer among female patients globally. Similarly, approximately 55% of cases occurred in developed territories.
𝐓𝐨 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐰𝐢𝐭𝐡 𝐋𝐚𝐭𝐞𝐬𝐭 𝐂𝐨𝐯𝐢𝐝𝟏𝟗 𝐈𝐦𝐩𝐚𝐜𝐭 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 @ https://www.coherentmarketinsights.com/insight/request-sample/2019
The development in research and development done by government and private healthcare institutions are promoting the growth of the global colon and rectal cancer drugs market. Till March 2018, the American Cancer Society (ACS) expend US$ 54 million in fundings on research on colon and rectal cancer concerning 92 research funds.
Development shortage in the neoadjuvant/adjuvant channel reps to treating the last stage of colorectal cancer displaying slight improvement in colon and rectal cancer drugs market. Based on the report established in 2016, by the National Center for Biotechnology Information (NCBI), the healthcare sector suffers from a shortage of clinical trials of perioperative, neoadjuvant, and adjuvant chemotherapy for colorectal liver metastases (CRLM) therapy.
Likewise, inappropriate restitution guidelines regarding colorectal cancer therapy in a few countries hinder the growth of the global colon and rectal cancer drugs market. Based on the comparison investigation issued in the American Society of Clinical Oncology (ASCO) 2018 conference, the estimation for metastatic colorectal cancer therapy in Washington is more elevated compared to British Columbia in Canada, resulting in the same outcome.
Based on the regional market, the global colon and rectal cancer drugs market is divided into North America, Latin America, the Middle East, Asia Pacific, Africa, and Europe. North American market has a principal place in the colon and rectal cancer drugs market. After that, the European market comes in second place. It happens because of the rising incidence speed of colorectal cancer in these regional markets. Based on the report published in 2012, by the World Cancer Research Fund International, the most elevated pace of colorectal cancer has been recorded in the Republic of Korea, Slovakia, and Hungary respectively. Correspondingly, a short span ago, a considerable amount of colorectal cancer cases was recorded in Oceania and Europe territory, while it delivers the lower incidence rates in Africa and Asia regional market.
𝐁𝐮𝐲 𝐍𝐨𝐰 𝐚𝐧𝐝 𝐆𝐞𝐭 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐅𝐅
𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 𝐓𝐨 𝐀𝐜𝐜𝐞𝐬𝐬 𝐅𝐮𝐥𝐥 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 @ https://www.coherentmarketinsights.com/promo/buynow/2019
Few of the major companies working in the global colon and rectal cancer drugs market contain Merck KGaA, Sanofi S.A. Sorrento Therapeutics, Takeda Pharmaceutical Company Ltd., AstraZeneca plc, Sirtex Medical Limited, Amgen Inc., Novartis International AG, Bayer AG, Bristol-Myers Squibb, Boehringer Ingelheim, and Daiichi Sankyo Company.
Major companies in the market are interested in the analysis and development of conducting clinical test studies and earning regulatory permission. In March 2018, Daiichi Sankyo began stage II research of DS-8201 in patients with HER2-expressing developed colorectal cancer. The beginning of HER2 stage clinical test analysis by Daiichi Sankyo for colorectal cancer treatment will allow improving the results in colorectal cancer patients. In March 2018, Bristol-Myers Squibb’s Opdivo (nivolumab) injection got authorized by the FDA. It is administrated intravenously for the therapy of adult and pediatric patients suffering from microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer.
The global colon and rectal cancer drugs market is segmented based on drug type, distribution channel, and the region as mentioned below:
By Drug Type:
• Single Drug
o Colon Cancer
o Rectal Cancer
• Irinotecan Hydrochloride
o Combination Drug
• Colon Cancer
o Rectal Cancer
By Distribution Channels:
• Hospitals Pharmacies
• Online Pharmacies
• Retail Pharmacies
• North America
• Asia Pacific
• Latin America
• Middle East
𝐓𝐨 𝐆𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐇𝐞𝐫𝐞 @ https://www.coherentmarketinsights.com/insight/request-pdf/2019
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027